PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

NCT04907370 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

532

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: PD-1 blocking antibody
DRUG: Gemcitabine
DRUG: Cisplatin (80mg/m2)
DRUG: Cisplatin (100mg/m2)
RADIATION: Intensity-modulated radiotherapy

Sponsor

Sun Yat-sen University

Collaborators

[object Object]